Leerink Partnrs Has Pessimistic View of Hologic Q2 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at Leerink Partnrs decreased their Q2 2025 earnings per share estimates for shares of Hologic in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical equipment provider will post earnings per share of $1.02 for the quarter, down from their previous forecast of $1.03. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. Leerink Partnrs also issued estimates for Hologic’s Q2 2026 earnings at $1.15 EPS, Q3 2026 earnings at $1.18 EPS, Q4 2026 earnings at $1.19 EPS and FY2026 earnings at $4.65 EPS.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same period in the previous year, the firm posted $0.89 earnings per share. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis.

Several other equities research analysts also recently issued reports on the company. Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Morgan Stanley reduced their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and dropped their price target for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Raymond James upped their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Monday, January 13th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Stock Performance

Shares of HOLX opened at $70.37 on Wednesday. The firm has a market capitalization of $15.88 billion, a P/E ratio of 21.13, a P/E/G ratio of 2.38 and a beta of 0.97. Hologic has a 52 week low of $68.61 and a 52 week high of $84.67. The stock has a 50 day moving average price of $74.46 and a two-hundred day moving average price of $78.36. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.88% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hologic

Several institutional investors have recently made changes to their positions in the stock. FMR LLC grew its stake in Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after acquiring an additional 2,174,093 shares in the last quarter. Mackenzie Financial Corp grew its position in shares of Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock valued at $66,506,000 after purchasing an additional 815,960 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after purchasing an additional 544,889 shares during the period. Marshall Wace LLP purchased a new stake in shares of Hologic in the second quarter worth $39,427,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Hologic by 21.6% during the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock valued at $188,243,000 after buying an additional 450,190 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.